P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 256 500 KRW 1.18% Market Closed
Market Cap: 2.7T KRW
Have any thoughts about
PharmaResearch Co Ltd?
Write Note

PharmaResearch Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PharmaResearch Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
P
PharmaResearch Co Ltd
KOSDAQ:214450
Short-Term Debt
â‚©250m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Short-Term Debt
â‚©1.6T
CAGR 3-Years
47%
CAGR 5-Years
41%
CAGR 10-Years
19%
SK Bioscience Co Ltd
KRX:302440
Short-Term Debt
â‚©0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Short-Term Debt
â‚©419.3B
CAGR 3-Years
41%
CAGR 5-Years
43%
CAGR 10-Years
13%
H
Hugel Inc
KOSDAQ:145020
Short-Term Debt
â‚©0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Short-Term Debt
â‚©5B
CAGR 3-Years
21%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

PharmaResearch Co Ltd
Glance View

Market Cap
2.7T KRW
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.

Intrinsic Value
278 629.45 KRW
Undervaluation 8%
Intrinsic Value
Price
P

See Also

What is PharmaResearch Co Ltd's Short-Term Debt?
Short-Term Debt
250m KRW

Based on the financial report for Sep 30, 2024, PharmaResearch Co Ltd's Short-Term Debt amounts to 250m KRW.

What is PharmaResearch Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 3Y
-74%

Over the last year, the Short-Term Debt growth was -98%. The average annual Short-Term Debt growth rates for PharmaResearch Co Ltd have been -74% over the past three years .

Back to Top